Bo Hansen - Karolinska Development Insider

KDEV -- Sweden Stock  

SEK 8.20  0.12  1.49%

Dr. Bo Jesper Hansen M.D. Ph.D. was Independent Chairman of the Board of Karolinska Development AB since October 1 2013. He is Member of the Asian Committee and Chairman of Remuneration and Audit Committees. He was Director of the Company since May 14 2013. He is also Chairman of Swedish Orphan Biovitrum AB and Board member of GenSpera Inc. Newron SA Ablynx NV Orphazyme AS and CMC Kontrast AB. His previous appointments include various positions in Swedish Orphan International AB since 1993 including CEO . He was Medical advisor for Synthelabo Pfizer Pharmacia and Yamanouchi. He is Founder of Scandinavian Medical Research.
Age: 57  Chairman Since 2013  Ph.D    
46 8 52 48 60 70

Management Efficiency

The company has return on total asset (ROA) of (4.09) % which means that it has lost $4.09 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 119.32 % meaning that it generated $119.32 on every $100 dollars invested by stockholders.
The company has accumulated 391.46 M in total debt with debt to equity ratio (D/E) of 158.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Karolinska Development AB has Current Ratio of 16.14 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 10 records


Anders TullgrenXbrane Biopharma AB
Claus BraestrupSaniona AB
Ulf WiinbergHansa Medical AB
Bjorn NilssonBioInvent International AB
Ulf LindbergKaressa Pharma Holding AB
deBethizySaniona AB
Gregory BatchellerXintela AB
Saeid EsmaeilzadehXbrane Biopharma AB
Martin NilssonKaressa Pharma Holding AB
Ulf TossmanKaressa Pharma Holding AB

Entity Summary

Karolinska Development AB is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. Karolinska Development AB was founded in 2003 and is headquartered in Stockholm, Sweden. Karolinska Development operates under Pharmaceuticals And Biosciences classification in Sweden and traded on Stockholm Stock Exchange. It employs 7 people.Karolinska Development AB (KDEV) is traded on Stockholm Stock Exchange in Sweden. It is located in Tomtebodav?gen 23 A and employs 7 people.

Karolinska Development Leadership Team

Hans Wigzell, Independent Chairman of the Board
Elisabet Gimbringer, Controller
Carl Sundberg, Director
Magnus Persson, Director
Jim Heusden, CEO
Maria Ferm, Executive Assistant
HansOlov Olsson, Director
Theresa Tse, Director
Viktor Drvota, Chief Investment Officer
Eva Montgomerie, Head of Accounting
Michael Owens, Controller
Yan Cheng, President Asia
Ulf Richenberg, General Counsel
Niclas Adler, Director
Tse Ping, Director
Christian Tange, CFO
Daniel Bolanowski, Business Analyst
Terje Kalland, Chief Scientific Officer
Vladimir Artamonov, Independent Director
Felicia Rittemar, Analyst
AnnSofie Sternas, Vice President IPR
Anders Harfstrand, Director
Bo Hansen, Chairman of the Board
Fredrik Jarrsten, CFO
Khalid Islam, Director
Gunilla Ekstrom, Vice President - Operations
Henrijette Richter, Director

Stock Performance Indicators

Current Sentiment - KDEV

Karolinska Development Investor Sentiment

Macroaxis portfolio users are evenly split in their trading attitude regarding investing in Karolinska Development AB. What is your trading attitude regarding investing in Karolinska Development AB? Are you bullish or bearish?
50% Bullish
50% Bearish

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.